The Estée Lauder Companies has announced a joint collaboration agreement with biotech company Atropos Therapeutics to identify and develop senescence modulating chemicals.
Senescence is the condition or process of deterioration with age – and, in a cell, refers to the loss of its power to divide and grow.
The joint development will focus on finding senomodulators from the botanical space for use in personal care products.
“Partnering with The Estée Lauder Companies, a leader in global prestige beauty that uses natural products, nicely complements our pipeline efforts to identify senomodulating chemicals by high content screening and using AI based drug design to interfere with activities necessary for geroconversion and senescence,” said Andrew Koff, Founder of Atropos Therapeutics.
He added: “With the three pipelines open, Atropos can move to the next stage of its development with isolated molecules in hand.”
“Atropos’ in-depth understanding of and its unique and well-validated approaches to identify senescence modulators will synergise well with our expertise in the natural product space,” commented Tom Mammone, Vice President of Skin Physiology and Pharmacology at The Estée Lauder Companies.
“Botanically derived senosuppressors are not only sure to be interesting new molecules – the utilisation of such will have great commercial potential for us.”
The field of senolytics, linked to the concept of well-ageing, has been cited as the next big thing in skin care and ingredients suppliers have begun to introduce active ingredients in this space.
An example is Mibelle Biochemistry’s newly launched Alpine Rose Active, which has been developed to ‘clean up’ age-promoting senescent skin cells.
